Camelot BioCapital Investor Lunch in Dubai — October 12, 2025
- Benjamin Radomski
- 2 days ago
- 1 min read
As part of our ongoing GCC activities, Camelot BioCapital (https://camelotbiocapital.com) will be hosting an exclusive investor lunch in Dubai on October 12, bringing together a select audience of family offices, institutional investors, and strategic partners.
BEV Capital is pleased to support this event by extending the invitation to our network, fostering connections with investors interested in Camelot’s differentiated biotech strategy.
Camelot is a seasoned biotech fund manager behind major exits such as Kite Pharma and Intercept, with over 100 years of combined experience, multiple FDA approvals, and leadership backgrounds at Wharton, Merck, Jazz, and Teva. The team is now raising its next fund, focused on early and clinical-stage investments in oncology and autoimmune diseases.
“We’re excited to meet with leading investors in the GCC region and share why Camelot represents a unique opportunity in biotech — combining deep scientific expertise with a proven track record of value creation,”
Colby Kash, Co-Founder, Camelot BioCapital
If you are based in Dubai or the region and would like to receive the full event details and registration information, please get in touch at info@bev.global
